Share This Article:

Expression of miR-16 is not a suitable reference for analysis of serum microRNAs in melanoma patients

Abstract Full-Text HTML Download Download as PDF (Size:205KB) PP. 647-651
DOI: 10.4236/jbise.2012.511080    3,677 Downloads   5,810 Views   Citations

ABSTRACT

Background: The evolving paradigm shift towards the molecular characterization of melanoma has expanded to include studies of microRNA (miRNA) expression. As miR-16 has been utilized as a normalizer in serum-based miRNA studies in several cancers, we evaluated miR-16 expression as a potential reference for normalization of serum miRNA expression in melanoma patients. Methods: 143 primary cutaneous melanoma patients who presented to New York University (NYU) Langone Medical Center for surgical resection of AJCC stage I-III disease were studied. In addition, sera samples from 60 control subjects were utilized including 22 healthy volunteers, 13 rheumatoid arthritis patients, 20 non-melanoma cancer patients (10 renal cell carcinoma and 10 bladder cancer), and 5 Atypical Mole Syndrome patients. The Kruskal-Wallis test (k = 6) or Wilcoxon test (k = 2) with Bonferroni correction was used for analyses of miR-16 expression in melanoma patients compared to various control groups, using raw Ct values directly. The Kruskal-Wallis test was used to compare miR-16 expression across stages of melanoma. The equivalence test for independent samples was used to test the equivalence of miR-16 expression among different groups. Results: No significant differential expression of miR-16 was observed between melanoma patients and healthy volunteers (Wilcoxon test, p = 0.37). However, miR-16 did show a significant difference in expression as it related to stage of melanoma (p = 0.015). Additionally, the equivalence test was unable to confirm equivalent expression of miR-16 in any melanoma versus control group pair. Conclusion: Our data indicate that miR-16 cannot be used as a universal normalizer in sera studies of melanoma patients.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Friedman, E. , Shang, S. , Fleming, N. , de Miera, E. , Hernando, E. , Shao, Y. and Osman, I. (2012) Expression of miR-16 is not a suitable reference for analysis of serum microRNAs in melanoma patients. Journal of Biomedical Science and Engineering, 5, 647-651. doi: 10.4236/jbise.2012.511080.

References

[1] Lu, J., Getz, G., Miska, E.A., et al. (2005) MicroRNA expression profiles classify human cancers. Nature, 435, 834-838. doi:10.1038/nature03702
[2] McManus, M.T. (2003) MicroRNAs and cancer. Seminars in Cancer Biology, 13, 253-258. doi:10.1016/S1044-579X(03)00038-5
[3] Vandesompele, J., De Preter, K., Pattyn, F., et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology, 3, RESEARCH0034.
[4] Dheda, K., Huggett, J.F., Chang, J.S., et al. (2005) The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Analytical Biochemistry, 344, 141-143. doi:10.1016/j.ab.2005.05.022
[5] Cortez, M.A. and Calin, G.A. (2009) MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases. Expert Opinion on Biological Therapy, 9, 703-711. doi:10.1517/14712590902932889
[6] Kroh, E.M., Parkin, R.K., Mitchell, P.S., et al. (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods, 50, 298-301. doi:10.1016/j.ymeth.2010.01.032
[7] Cortez, M.A., Bueso-Ramos, C., Ferdin, J., et al. (2011) MicroRNAs in body fluids—The mix of hormones and biomarkers. Nature Reviews: Clinical Oncology, 8, 467-477.
[8] Song, J.N., Bai, Z.G., Han, W., et al. (2012) Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Digestive Diseases and Sciences, 57, 897-904. doi:10.1007/s10620-011-1981-7
[9] Zhu, H.-T., Dong, Q.-Z., Wang, G., et al. (2012) Identification of suitable reference genes for qRT-PCR analysis of circulating microRNAs in hepatitis B virus-infected patients. Molecular Biotechnology, 50, 49-56. doi:10.1007/s12033-011-9414-6
[10] Wich, L.G., Hamilton, H.K., Shapiro, R.L., et al. (2009) Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. American Journal of Translational Research, 1, 35-43.
[11] Kopf, A.W., Friedman, R.J. and Rigel, D.S. (1990) A typical mole syndrome. Journal of the American Academy of Dermatology, 22, 117-118. doi:10.1016/S0190-9622(08)80006-0
[12] Haller, F., Kulle, B., Schwager, S., et al. (2004) Equivalence test in quantitative reverse transcription polymerase chain reaction: Confirmation of reference genes suitable for normalization. Analytical Biochemistry, 335, 1-9. doi:10.1016/j.ab.2004.08.024
[13] Peltier, H.J. and Latham, G.J. (2008) Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA, 14, 844-852. doi:10.1261/rna.939908
[14] Hunter, M.P., Ismail, N., Zhang, X.L., et al. (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE, 3, e3694. doi:10.1371/journal.pone.0003694
[15] Valadi, H., Ekstr?m, K., Bossios, A., et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 9, 654-659. doi:10.1038/ncb1596
[16] Skog, J., Wurdinger, T., Van Rijn, S., et al. (2008) Glio-blastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology, 10, 1470-1476. doi:10.1038/ncb1800
[17] Pigati, L., Yaddanapudi, S.C.S., Iyengar, R., et al. (2010) Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS ONE, 5, e13515. doi:10.1371/journal.pone.0013515
[18] Ng, E.K., Chong, W.W., Jin, H., et al. (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut, 58, 1375-1381. doi:10.1136/gut.2008.167817
[19] Shen, J., Todd, N.W., Zhang, H., et al. (2011) Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Laboratory Investigation, 91, 579-587. doi:10.1038/labinvest.2010.194
[20] Huang, Z.H., Huang, D., Ni, S.J., et al. (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. International Journal of Cancer, 127, 118-126. doi:10.1002/ijc.25007

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.